Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2012

01.08.2012 | Original Article

Evaluation of Early Atherosclerosis in Patients with Inflammatory Bowel Disease

verfasst von: Hasan Kayahan, Ismail Sari, Nesat Cullu, Fahize Yuksel, Serdal Demir, Mesut Akarsu, Yigit Goktay, Belkis Unsal, Hale Akpinar

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Data regarding early atherosclerosis and inflammatory bowel disease are limited and conflicting results are present.

Aims

The purpose of this study was to evaluate serological and sonographical evidence of subclinical vascular involvement in patients with inflammatory bowel disease.

Methods

Thirty-nine patients with inflammatory bowel disease (20 Crohn's disease, and 19 ulcerative colitis patients) and 31 healthy controls were consecutively enrolled in the study. Flow mediated dilatation of the brachial artery and intima media thickness assessments of the common carotid artery were measured sonographically. Soluble CD40 ligand levels were evaluated. Crohn's disease activity index and modified Truelove-Witt’s criteria were also noted.

Results

Age, sex distribution, serum lipids, smoking status, and intima media thickness of the common carotid artery were similar between the inflammatory bowel disease patients and controls (p > 0.05). However, both endothelium dependent and independent flow mediated dilatation values were significantly impaired in the inflammatory bowel disease group compared with healthy controls (p < 0.05). Erythrocyte sedimentation rate, C-reactive protein and soluble CD40 ligand values were significantly increased in inflammatory bowel disease patients compared with controls (p < 0.05), and soluble CD40 ligand was negatively correlated with flow mediated dilatation (r = −0.3, p < 0.05). Flow mediated dilatation was significantly predicted from the concentrations of C-reactive protein and soluble CD40 ligand.

Conclusion

Functional atherosclerosis is present in inflammatory bowel disease before early structural changes occur in vasculature. Higher sCD40L may indicate worse vascular outcome for IBD.
Literatur
1.
Zurück zum Zitat Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–2138.PubMedCrossRef Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–2138.PubMedCrossRef
2.
Zurück zum Zitat Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.PubMedCrossRef Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.PubMedCrossRef
3.
Zurück zum Zitat Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol. 2000;50:397–404.PubMedCrossRef Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol. 2000;50:397–404.PubMedCrossRef
4.
Zurück zum Zitat Poredos P. Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med. 2004;9:46–54.PubMedCrossRef Poredos P. Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med. 2004;9:46–54.PubMedCrossRef
6.
Zurück zum Zitat Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40:S253–S259.PubMedCrossRef Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40:S253–S259.PubMedCrossRef
7.
Zurück zum Zitat Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106:741–747.PubMedCrossRef Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106:741–747.PubMedCrossRef
8.
Zurück zum Zitat van Leuven SI, Hezemans R, Levels JH, et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn’s disease. J Lipid Res. 2007;48:2640–2646.PubMedCrossRef van Leuven SI, Hezemans R, Levels JH, et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn’s disease. J Lipid Res. 2007;48:2640–2646.PubMedCrossRef
9.
Zurück zum Zitat Schinzari F, Armuzzi A, De Pascalis B, et al. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn’s disease. Clin Pharmacol Ther. 2008;83:70–76.PubMedCrossRef Schinzari F, Armuzzi A, De Pascalis B, et al. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn’s disease. Clin Pharmacol Ther. 2008;83:70–76.PubMedCrossRef
10.
Zurück zum Zitat Roifman I, Sun YC, Fedwick JP, et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2009;7:175–182.PubMedCrossRef Roifman I, Sun YC, Fedwick JP, et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2009;7:175–182.PubMedCrossRef
11.
Zurück zum Zitat Papa A, Santoliquido A, Danese S, et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:839–846.PubMedCrossRef Papa A, Santoliquido A, Danese S, et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:839–846.PubMedCrossRef
12.
Zurück zum Zitat Kocaman O, Sahin T, Aygun C, Senturk O, Hulagu S. Endothelial dysfunction in patients with ulcerative colitis. Inflamm Bowel Dis. 2006;12:166–171.PubMedCrossRef Kocaman O, Sahin T, Aygun C, Senturk O, Hulagu S. Endothelial dysfunction in patients with ulcerative colitis. Inflamm Bowel Dis. 2006;12:166–171.PubMedCrossRef
13.
Zurück zum Zitat Haapamaki J, Roine RP, Turunen U, Farkkila MA, Arkkila PE. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis. 2011;5:41–47.PubMedCrossRef Haapamaki J, Roine RP, Turunen U, Farkkila MA, Arkkila PE. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis. 2011;5:41–47.PubMedCrossRef
14.
Zurück zum Zitat Dagli N, Poyrazoglu OK, Dagli AF, et al. Is inflammatory bowel disease a risk factor for early atherosclerosis? Angiology. 2010;61:198–204.PubMedCrossRef Dagli N, Poyrazoglu OK, Dagli AF, et al. Is inflammatory bowel disease a risk factor for early atherosclerosis? Angiology. 2010;61:198–204.PubMedCrossRef
15.
Zurück zum Zitat Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol. 2007;102:1050–1055.PubMedCrossRef Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol. 2007;102:1050–1055.PubMedCrossRef
16.
Zurück zum Zitat Broide E, Schopan A, Zaretsky M, Kimchi NA, Shapiro M, Scapa E. Intima-media thickness of the common carotid artery is not significantly higher in Crohn’s disease patients compared to healthy population. Dig Dis Sci. 2011;56:197–202.PubMedCrossRef Broide E, Schopan A, Zaretsky M, Kimchi NA, Shapiro M, Scapa E. Intima-media thickness of the common carotid artery is not significantly higher in Crohn’s disease patients compared to healthy population. Dig Dis Sci. 2011;56:197–202.PubMedCrossRef
17.
Zurück zum Zitat Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol. 2007;102:662–667.PubMedCrossRef Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol. 2007;102:662–667.PubMedCrossRef
18.
Zurück zum Zitat Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845.PubMedCrossRef Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845.PubMedCrossRef
19.
Zurück zum Zitat Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599–2610.PubMedCrossRef Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599–2610.PubMedCrossRef
20.
Zurück zum Zitat Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979.PubMedCrossRef Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979.PubMedCrossRef
21.
Zurück zum Zitat Sari I, Okan T, Akar S, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford). 2006;45:283–286.CrossRef Sari I, Okan T, Akar S, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford). 2006;45:283–286.CrossRef
22.
Zurück zum Zitat Ozbalkan Z, Efe C, Cesur M, et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis. 2010;212:377–382.PubMedCrossRef Ozbalkan Z, Efe C, Cesur M, et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis. 2010;212:377–382.PubMedCrossRef
23.
Zurück zum Zitat Sherer Y, Zinger H, Shoenfeld Y. Atherosclerosis in systemic lupus erythematosus. Autoimmunity. 2010;43:98–102. Sherer Y, Zinger H, Shoenfeld Y. Atherosclerosis in systemic lupus erythematosus. Autoimmunity. 2010;43:98–102.
24.
Zurück zum Zitat Jackson LM, O’Gorman PJ, O’Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM Mon J Assoc Phys. 1997;90:183–188. Jackson LM, O’Gorman PJ, O’Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM Mon J Assoc Phys. 1997;90:183–188.
25.
Zurück zum Zitat Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 1993;34:247–251.PubMedCrossRef Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 1993;34:247–251.PubMedCrossRef
26.
Zurück zum Zitat Scaldaferri F, Lancellotti S, Pizzoferrato M, De Cristofaro R. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. World J Gastroenterol. 2011;17:594–608.PubMedCrossRef Scaldaferri F, Lancellotti S, Pizzoferrato M, De Cristofaro R. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. World J Gastroenterol. 2011;17:594–608.PubMedCrossRef
27.
Zurück zum Zitat Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:896–899.PubMedCrossRef Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:896–899.PubMedCrossRef
28.
Zurück zum Zitat Lutgens E, Lievens D, Beckers L, Donners M, Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med. 2007;17:118–123.PubMedCrossRef Lutgens E, Lievens D, Beckers L, Donners M, Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med. 2007;17:118–123.PubMedCrossRef
29.
Zurück zum Zitat Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother. 2004;38:1500–1508.PubMedCrossRef Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother. 2004;38:1500–1508.PubMedCrossRef
30.
Zurück zum Zitat Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut. 2003;52:1435–1441.PubMedCrossRef Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut. 2003;52:1435–1441.PubMedCrossRef
31.
Zurück zum Zitat Koutroubakis IE, Theodoropoulou A, Xidakis C, et al. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16:1147–1152.PubMedCrossRef Koutroubakis IE, Theodoropoulou A, Xidakis C, et al. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16:1147–1152.PubMedCrossRef
Metadaten
Titel
Evaluation of Early Atherosclerosis in Patients with Inflammatory Bowel Disease
verfasst von
Hasan Kayahan
Ismail Sari
Nesat Cullu
Fahize Yuksel
Serdal Demir
Mesut Akarsu
Yigit Goktay
Belkis Unsal
Hale Akpinar
Publikationsdatum
01.08.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2148-x

Weitere Artikel der Ausgabe 8/2012

Digestive Diseases and Sciences 8/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.